About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Disseny, síntesi i caracterització de nanosistemes terapèutics biodegradables
IP: Joaquin Seras Franzoso
IP: Maria del Pilar Reimundo Diaz-Fierros
IP: Obtenció i us de vesícules extracel·lulars com vehicles per proteïnes i biomolècules
IP: Diana Fernandes de Rafael Collaborators: Fco Javier De la Torre Fdez de Vega, Simon Schwartz Navarro, Sandra Mancilla Zamora, Belen Garcia Prats Funding agency: Instituto de Salud Carlos III Funding: 177500 Reference: PI24/00745 Duration: 01/01/2025 - 31/12/2027
IP: José Raul Herance Camacho Collaborators: Sofia Rodriguez Fernandez, Sergi Velasco Vila, Clara Ramírez Serra, Azahara Maria Palomar Muñoz, Cristina Gamez Cenzano, Jana Vidal Otero, Carolina Aparicio Gomez, Alberto Roque Pérez, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán, Maria Nazarena Pizzi, Emily Betancourt Fernández, Enrique Franky Vargas, Martha Sahylí Ortega Pijeira, Emily Betancourt Fernández Funding agency: Instituto de Salud Carlos III Funding: 252500 Reference: PI24/01356 Duration: 01/01/2025 - 31/12/2027
IP: Joaquin Seras Franzoso Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 82800 Reference: EXPAND-EV/EC/MSCA-SE/2024/SERAS Duration: 01/01/2025 - 31/12/2028
IP: - Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 251971.2 Reference: SPM40_F.ANDRADE_MSCA-DN2023 Duration: 01/11/2024 - 31/10/2028
The study results show that the local presence of IL-1β promotes the development of myeloid cells with an immunosuppressive function.
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.
